The Roche Tecentriq first-line treatment for advanced ovarian cancer Phase III study did not reach the primary endpoint of PFS.

The IMagyn050 study used a multi-center, randomized, double-blind design that primarily assessed differences in efficacy and safety in patients with Stage III to IV ovarian cancer who were undergoing new assisted or auxiliary treatments in The Therapeutics of Tecentriq, Avastin, Sequoia, Andau, Andauin, and Sequoia, first-line treatment.
studies set double endpoints, including PFS and OS assessed by the researchers, and stratified in the intended treatment population and pD-L1 positive population.
key secondary endpoints include ORR, safety and tolerance, and improvements in abdominal pain bloating reported by patients.
the oS primary endpoint of the IMagyn050 study is not yet ripe, roche will continue to follow-up research until the next scheduled analysis time node.
the results of the IMagyn050 study will also affect Tecentriq's gynecological tumor development program.
ovarian cancer is the eighth most common cancer in women worldwide, with 300,000 new confirmed cases each year.
ovarian cancer patients usually progress to the advanced stage at the time of diagnosis, with a 5-year survival rate of less than 30%, and is therefore a major cause of death for gynaecological malignancies. "Advanced ovarian cancer is still one of the most difficult to treat invasive cancers, and we are disappointed with the results of the IMagyn050 study, but will continue to work to improve outcomes for patients with advanced ovarian cancer," said Levi Garraway,
's chief medical officer and global head of product development at Roche.
"